Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2022 | Tagraxofusp-based therapy to eradicate MRD in patients with AML prior to alloHCT

Gary Schiller, MD, University of California, Los Angeles, Los Angeles, CA, describes an ongoing Phase Ib/II trial investigating the efficacy and safety of tagraxofusp with or without azacitidine in patients with acute myeloid leukemia (AML) with detectable measurable residual disease (MRD). Patients who achieve MRD negativity after one cycle will then receive allogeneic hematopoietic cell transplantation (alloHCT). No more than two cycles of the investigational treatment will be administrated in this trial. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Constellation: Research Funding; Sellas: Research Funding; Samus: Research Funding; Sangamo: Research Funding; Amgen: Current equity holder in publicly-traded company, Honoraria; Medimmune: Research Funding; FujiFilm: Research Funding; Millennium: Research Funding; Daiichi-Sankyo: Research Funding; Stemline: Research Funding; Deciphera: Research Funding; Genentech-Roche: Research Funding; Gilead: Research Funding; Karyopharm: Research Funding, Speakers Bureau; Incyte: Other: speaker fees, Research Funding, Speakers Bureau; Deltafly: Research Funding; CTI: Research Funding; Ono Pharma: Honoraria; Arog: Research Funding; Forma: Research Funding; Novartis: Honoraria, Other: Speaker fees, Research Funding; Johnson & Johnson: Current equity holder in publicly-traded company; AVM Biopharma: Research Funding; Cellectis: Research Funding; Trovagen: Research Funding; Glycomimetics: Research Funding; Pfizer: Research Funding; AstraZeneca: Honoraria; Kite, a Gilead Company: Research Funding, Speakers Bureau; Cyclacel: Research Funding; AltruBio: Research Funding; Celgene: Consultancy, Research Funding, Speakers Bureau; Janssen: Research Funding; Stemline: Speakers Bureau; Mateon: Research Funding; Geron: Research Funding; Cellerant: Research Funding; Regimmune: Research Funding; PreCOG LLC: Research Funding; Actuate: Research Funding; Jazz: Consultancy; Onconova: Research Funding; Gamida: Research Funding; Takeda: Research Funding; Tolero: Research Funding; Bristol Myers Squibb: Current equity holder in publicly-traded company, Speakers Bureau; Astellas: Research Funding, Speakers Bureau; Agios: Consultancy, Honoraria; Actinium: Research Funding; AbbVie: Research Funding, Speakers Bureau.